Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model

Temozolomide (TMZ) chemotherapy for glioblastoma (GBM) is generally well tolerated at standard doses but it can cause side effects. GBMs overexpress microRNA-21 and microRNA-10b, two known oncomiRs that promote cancer development, progression and resistance to drug treatment. We hypothesized that sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhotra, Meenakshi, Sekar, Thillai Veerapazham, Ananta, Jeyarama S., Devulapally, Rammohan, Afjei, Rayhaneh, Babikir, Husam A., Paulmurugan, Ramasamy, Massoud, Tarik F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940368/
https://www.ncbi.nlm.nih.gov/pubmed/29765554
http://dx.doi.org/10.18632/oncotarget.25135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940368/
https://www.ncbi.nlm.nih.gov/pubmed/29765554
http://dx.doi.org/10.18632/oncotarget.25135

Ejemplares similares